Lilly (Eli)
LLY · Regulatory · 08 Sep 2026, 04:05 UTC · 1 sources
Relevance 52/100 · MediumInitial public phase, not yet validated against real outcomes. The impact score is not investment advice or a price forecast.
1-year price history
Source: Yahoo FinanceThe chart uses daily closes adjusted by the available provider. There may be delays, gaps or differences versus the official source.
Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
- Sector Healthcare · Drug Manufacturers - General
- Website https://www.lilly.com
Relevance
How much this news should matter to you. NOT a probability of rising.
See score breakdown
News sentiment
How the published information reads on its face — not compared with what the market expected.
Market reading
FDA_APPROVAL: outcome=FAVORABLE (+2.0); afecta al negocio principal (mantiene magnitud).
What the event says for the stock relative to what the market expected. Initial heuristic, not yet validated against real returns. Methodology regulatory_v1. Will be recalibrated with real returns.
Observed reaction
After-the-fact measurement. Never used to recompute the event's classification.
Why it matters
La FDA ha autorizado Elecsys pTau217, un test sanguíneo para cambios cerebrales asociados al Alzheimer; es una aprobación regulatoria que podría facilitar la identificación de pacientes y beneficiar a compañías con fármacos para Alzheimer como LLY.
Event data
Disclaimer
This is not financial advice or a buy/sell recommendation. Relevance and market reading are experimental and have not been validated against real returns -- they must never be read as a probability that the stock will rise.